
A finance graduate answered a housing problem with a classified ad and found a scientist instead. Two decades later, Brian Slingerland is still building companies where business discipline meets difficult biology.
No scope, no needle - just a cup of urine and 60 genes worth of warning. Convergent Genomics is betting that bladder cancer leaves a paper trail years before a doctor can see it.